Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 - Jänicke, F; Prechtl, A; Thomssen, C (J Natl Cancer Inst, 2001)
et al.